We incubate and accelerate therapeutic and therapeutic platform ventures. Since early 2018, BaseLaunch has supported nine ventures that have, in total, raised over 100 million USD in financing. Several pharma collaborations have been initiated and one company has been sold. As of December 2019, we have added another four companies to our portfolio. Furthermore, BaseLaunch has been contributing to the development of six more ventures in the Basel Area (ABBA therapeutics, Alibion, Avicenna Oncology, Captor Therapeutics, FoRx Therapeutics, Sunregen.)
During its first phase (2017-2019), BaseLaunch was supported by Roche, Novartis Ventures, J&J, Pfizer and Roivant. Because of our success, in 2020 the second phase has now been launched and the available funding increased to up to 500,000 USD per company. Partners for the second phase will be made public over the coming months.
BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.